AETHLON MEDICAL INC (AEMD) - Dilution Analysis

10-Q filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 2,585,316 → 761,210

10-K filing | 2.6M shares outstanding

8-K filing: Stock split 1-for-8 | Outstanding: 13,962,266 → 1,745,283

8-K filing: Aethlon Medical, Inc. closed an inducement offer to exercise existing Class A and Class B Warrants on March 17, 2025, resulting in the issuance of 6,200,000 shares of common stock and new unregistered warrants, with gross proceeds of approximately $2,316,320 million. ($2316320.0M proceeds)

10-Q filing | 14.0M shares outstanding

10-Q filing | 13.9M shares outstanding

10-Q filing | 13.9M shares outstanding

10-K filing | 13.9M shares outstanding

8-K filing: Aethlon Medical, Inc. priced and closed a best-efforts public offering of common stock, pre-funded warrants, and accompanying warrants on May 17, 2024, with net proceeds of approximately $3.84 million.

POS AM filing: Aethlon Medical, Inc. files Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 relating to the offering and sale of up to 8,100,000 common shares, pre-funded warrants to purchase up to 8,100,000 common shares, Class A and B Common Stock Purchase Warrants to purchase up to 16,200,000 shares of Common Stock and a placement agent warrant to purchase up to 324,000 shares of Common Stock.

S-1/A filing: This S-1/A filing registers the offering of common stock, pre-funded warrants, Class A warrants, Class B warrants, and shares issuable upon exercise of these warrants.

S-1/A filing: The company is offering common stock, pre-funded warrants and warrants to purchase common stock in a best-efforts offering, with Maxim Group LLC acting as the exclusive placement agent.

S-1/A filing: The company is offering up to 4,651,162 shares of common stock, pre-funded warrants and warrants in a best-efforts offering with Maxim Group LLC as the placement agent.

10-Q filing | 2.5M shares outstanding

10-Q filing | 2.5M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 24,314,759 → 2,431,475

10-Q filing | 24.3M shares outstanding

10-K filing | 24.8M shares outstanding

10-Q filing | 22.9M shares outstanding

10-Q filing | 20.7M shares outstanding

10-Q filing | 22.9M shares outstanding

10-K filing | 15.8M shares outstanding

10-Q filing | 15.4M shares outstanding

10-Q filing | 15.4M shares outstanding

S-3 filing: The company intends to offer and sell shares of its common stock with total gross proceeds of up to $60,000,000 using a shelf registration process.

10-Q filing | 15.4M shares outstanding

10-K filing | 15.4M shares outstanding

8-K filing: Aethlon Medical, Inc. announced a registered direct offering of 1,380,555 shares at $9.00 per share, an open market sale of 626,000 shares, and the issuance of approximately 1.17 million shares upon the exercise of outstanding warrants. ($12.43M proceeds)

10-Q filing | 12.1M shares outstanding

10-Q filing | 12.1M shares outstanding

10-Q filing | 12.1M shares outstanding

10-K filing | 12.1M shares outstanding

S-3 filing: The company may offer up to $25,000,000 of any combination of common stock and debt securities. They are also offering common stock with an aggregate offering price of up to $7,495,000 at prevailing market prices through H.C. Wainwright & Co., LLC.

10-Q filing | 9.3M shares outstanding

8-K filing: Aethlon Medical, Inc. issued 610,762 shares of common stock at an average price of $0.93 per share from August 20, 2019 to January 17, 2020, resulting in net proceeds of $568,433 and terminated the ATM Prospectus Supplement on January 17, 2020. ($0.57M proceeds)